Protein changes in myasthenia gravis with Ravulizumab
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study looks at certain proteins in the blood of people with myasthenia gravis who are taking the drug Ravulizumab. It aims to understand how the drug affects the body and may help improve treatment for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a form of myasthenia gravis called 'generalized' that is positive for AChR antibodies.
- Your doctor has prescribed or is considering the drug Ravulizumab for your condition.
- You do not have other autoimmune diseases (like lupus or rheumatoid arthritis).
- You do not have an active cancer or infection right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
This study looks for markers that may predict a favorable response to complement inhibitor drugs in people with generalized myasthenia gravis. It aims to identify who might benefit most from this treatment.
This Phase 3 trial tests rituximab (an immune system medicine) to see if it improves myasthenia gravis (MG) symptoms and function. It’s for adults with confirmed MG and moderate-to-severe impact on daily activities despite current care.
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
This study tests whether starting ravulizumab early, after plasma exchange or IVIg, can help people with a severe myasthenia gravis crisis who are in the intensive care unit. It aims to see if it improves their condition.
Hear when a new Myasthenia Gravis Generalised trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.